AEMD Aethlon Medical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AEMD

Price (delayed)

$1.5

Market cap

$3.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.09

Enterprise value

-$3.44M

Aethlon is focused on addressing unmet needs in global health. The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier ...

Highlights
The company's debt fell by 28% YoY and by 9% QoQ
Aethlon Medical's EPS has increased by 32% YoY but it has decreased by 2.6% QoQ
The net income has increased by 8% year-on-year but it has declined by 5% since the previous quarter
The company's equity has shrunk by 56% YoY and by 26% QoQ
The quick ratio has contracted by 47% YoY and by 36% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.aethlonmedical.com
Peers: INO BRKR AXDX PACB

Key stats

What are the main financial stats of AEMD
Market
Shares outstanding
2.62M
Market cap
$3.93M
Enterprise value
-$3.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.49
Price to sales (P/S)
6.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-5.99
Earnings
Revenue
$574,245
EBIT
-$12.25M
EBITDA
-$11.89M
Free cash flow
-$10.77M
Per share
EPS
-$5.09
Free cash flow per share
-$4.28
Book value per share
$3.05
Revenue per share
$0.23
TBVPS
$4.15
Balance sheet
Total assets
$10.44M
Total liabilities
$2.83M
Debt
$724,848
Equity
$7.61M
Working capital
$6.15M
Liquidity
Debt to equity
0.1
Current ratio
3.93
Quick ratio
3.85
Net debt/EBITDA
0.62
Margins
EBITDA margin
-2,071.3%
Gross margin
100%
Net margin
-2,133.2%
Operating margin
-2,199.1%
Efficiency
Return on assets
-86.6%
Return on equity
-106.3%
Return on invested capital
-731.1%
Return on capital employed
-146.9%
Return on sales
-2,133.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AEMD stock price

How has the Aethlon Medical stock price performed over time
Intraday
-1.32%
1 week
6.38%
1 month
-13.79%
1 year
-66.67%
YTD
-31.51%
QTD
-10.71%

Financial performance

How have Aethlon Medical's revenue and profit performed over time
Revenue
$574,245
Gross profit
$574,245
Operating income
-$12.63M
Net income
-$12.25M
Gross margin
100%
Net margin
-2,133.2%
The company's net margin has surged by 98% YoY but it fell by 5% QoQ
Aethlon Medical's operating margin has soared by 98% YoY but it has decreased by 6% from the previous quarter
The net income has increased by 8% year-on-year but it has declined by 5% since the previous quarter
The company's operating income fell by 6% QoQ but it rose by 4.4% YoY

Growth

What is Aethlon Medical's growth rate over time

Valuation

What is Aethlon Medical stock price valuation
P/E
N/A
P/B
0.49
P/S
6.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-5.99
Aethlon Medical's EPS has increased by 32% YoY but it has decreased by 2.6% QoQ
The P/B is 84% below the 5-year quarterly average of 3.1 and 18% below the last 4 quarters average of 0.6
The company's equity has shrunk by 56% YoY and by 26% QoQ
The price to sales (P/S) is 92% lower than the 5-year quarterly average of 83.9 and 46% lower than the last 4 quarters average of 12.1

Efficiency

How efficient is Aethlon Medical business performance
Aethlon Medical's return on sales has surged by 98% YoY but it has decreased by 5% QoQ
The ROE has contracted by 38% YoY and by 27% from the previous quarter
The ROA has contracted by 30% YoY and by 24% from the previous quarter
Aethlon Medical's ROIC has increased by 18% YoY but it has decreased by 16% from the previous quarter

Dividends

What is AEMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AEMD.

Financial health

How did Aethlon Medical financials performed over time
The company's total assets fell by 50% YoY and by 19% QoQ
The quick ratio has contracted by 47% YoY and by 36% from the previous quarter
The company's debt is 90% lower than its equity
The debt to equity has surged by 67% year-on-year and by 25% since the previous quarter
The company's equity has shrunk by 56% YoY and by 26% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.